I-Tind for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Mid-term outcomes from a multicenter cohort
Abstract
Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract symptoms (LUTS) in aging men, significantly impacting quality of life. Although pharmacological therapies, especially alpha-blockers, are the standard first-line treatment, their long-term adherence is limited by side effects and insufficient symptom control. Transurethral resection of the prostate (TURP) remains the surgical gold standard but is associated with notable morbidity, prompting interest in minimally invasive alternatives. The temporary implantable nitinol device (I-Tind) offers a tissue-sparing approach designed to remodel the prostatic urethra and relieve LUTS without compromising sexual function. This multicenter prospective study evaluated the safety, efficacy, and functional outcomes of I-Tind in 120 patients with symptomatic BPH unresponsive to alpha-blockers, treated between 2019 and 2023. Follow-up assessments were done at 3, 6, and 12 months. The study showed significant improvements in urinary flow and symptom scores. Mean Qmax improved from 7.6 to 15.7 mL/s, and mean IPSS decreased from 21.5 to 9.7 at 12 month-follow-up (p < 0.001). Quality of life measures also improved, and sexual and ejaculatory functions were fully preserved. The procedure was well-tolerated, with all implants successfully retrieved after a mean of 6 days and a low complication rate. I-Tind appears to be a safe and effective minimally invasive option for selected BPH patients, combining symptom relief with…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 120 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.